SHILPAMED
Shilpa Medicare
Each stock's 10,000-path forecast, rendered as light.
Shilpa Medicare (SHILPAMED) Stock Analysis & Case Study
Is SHILPAMED a good buy? The data-driven verdict.
on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, Shilpa Medicare (SHILPAMED) worth a closer look, a Downstox Snapshot Score of 58/100, weighing a 69% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
SHILPAMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of SHILPAMED history (31%/yr drift, 43%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SHILPAMED 2027 | ₹395 | ₹686 | ₹1,192 | +24% |
| SHILPAMED 2028 | ₹392 | ₹853 | ₹1,853 | +55% |
| SHILPAMED 2029 | ₹409 | ₹1,049 | ₹2,764 | +90% |
| SHILPAMED 2030 | ₹433 | ₹1,316 | ₹4,053 | +139% |
| SHILPAMED 2031 | ₹471 | ₹1,651 | ₹5,628 | +199% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SHILPAMED goes up, or doubles?
The bull case for SHILPAMED
- A 10,000-path probability model puts a 69% chance the price is higher in a year, with a median target of ₹686 (+24%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,764.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹409.
SHILPAMED volatility & expected range, how bumpy is the ride?
Over the last 2.0 years SHILPAMED compounded at 31%/year with annualized volatility of 43%. That volatility implies a 1-year 80% range of ₹395–₹1,192, the honest backbone behind any single price target.
SHILPAMED price forecast, the full 60-month probability fan
SHILPAMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SHILPAMED hits common targets within the simulated horizon?
Full multi-horizon detail on the SHILPAMED price target & forecast page.
SHILPAMED MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy SHILPAMED with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 34.7% | 2.9× |
| DhanCHEAPEST | 34.7% | 2.9× |
Compare every broker on the SHILPAMED MTF page.
SHILPAMED vs peers,sector comparison
About Shilpa Medicare: sector, index & market-cap context
Shilpa Medicare (SHILPAMED) is an NSE-listed company.
How the SHILPAMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Shilpa Medicare's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SHILPAMED analysis, FAQs
Is Shilpa Medicare (SHILPAMED) a good buy?
On the numbers, Shilpa Medicare (SHILPAMED) worth a closer look, a Downstox Snapshot Score of 58/100, weighing a 69% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SHILPAMED overvalued or undervalued?
Valuation ratios for SHILPAMED are tracked live on Downstox.
What is the SHILPAMED share price target for 2031?
SHILPAMED's probability-weighted 2031 median target is ₹1,651, with an 80% range of ₹471–₹5,628 (10,000-path Monte-Carlo).
What is the probability SHILPAMED doubles in 5 years?
The modelled probability of SHILPAMED reaching ₹1,103 (2×) within 5 years is 67%.
What is the bull case for SHILPAMED?
A 10,000-path probability model puts a 69% chance the price is higher in a year, with a median target of ₹686 (+24%).
What are the risks in SHILPAMED?
No model or past record guarantees future returns, treat this as one input, not a decision.